|
시장보고서
상품코드
2052683
미세잔존질환 검사 시장 : 기술별, 용도별, 최종사용자별, 지역별Minimal Residual Disease Testing Market, By Technology, By Application, By End User, By Geography |
||||||
미세잔존질환(MRD) 검사 시장은 2026년에 28억 9,000만 달러로 추정되며, 2033년까지 63억 9,000만 달러에 달할 것으로 전망됩니다. 2026년부터 2033년까지 CAGR 12.0%로 성장할 것으로 예측됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 28억 9,000만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 12.00% | 2033년 시장 규모 예측: | 63억 9,000만 달러 |
미세잔존질환(MRD) 검사는 초기 치료 후 체내에 남아있을 수 있는 극소량의 암세포를 검출하는 검사입니다. 이는 혈액내과 및 종양내과 의사가 치료 반응을 모니터링하고 환자의 예후를 예측하는 데 중요한 도구입니다. MRD 검사를 통해 의사는 다른 방법보다 조기에 질병 재발 위험이 높은 환자를 식별할 수 있습니다. 이를 통해 추가 치료나 보다 면밀한 모니터링이 필요한지 여부를 판단하는 데 도움이 됩니다. 다중 파라미터 유세포 분석법, 알러지 특이적 올리고뉴클레오티드 정량 PCR, 차세대 시퀀싱 등 여러 기술이 MRD를 고감도로 검출하기 위해 사용되고 있습니다. 다양한 종류의 혈액암에서 MRD 검사의 적용 범위가 확대되고 기술이 발전함에 따라 향후 몇 년 동안 시장은 크게 성장할 것으로 예상됩니다.
시장 역학
세계 미세잔존질환(MRD) 검사 시장은 혈액암 발생률 증가, 치료 모니터링에 MRD 검사 도입 확대, 의사들 사이에서 MRD 검사에 대한 인식이 높아짐에 따라 성장세를 보이고 있습니다. 그러나 숙련된 전문가 부족, 검사 방법의 높은 비용, 일부 지역의 보험 환급 문제 등이 시장 성장을 저해하는 요인으로 작용하고 있습니다. 감도를 높인 제품이나 자동화 플랫폼을 갖춘 업체들의 다양한 신제품 출시는 중요한 성장 기회를 가져오고 있습니다. 예를 들어, 맞춤형 치료와 액체 생검 기술은 새로운 분야입니다. 기업과 연구기관과의 협력도 새로운 지역으로의 시장 확대를 뒷받침하고 있습니다. COVID-19 팬데믹이 의료 자원에 미치는 영향은 어려운 과제이지만, 원격의료와 재택 검체 채취는 현재 상황에서 MRD 모니터링을 지속할 수 있도록 돕고 있습니다.
본 조사의 주요 특징
- 이 조사에서는 각 부문의 잠재적인 수익 성장 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요한 인사이트를 제공합니다.
- 이 보고서는 세계 미세잔존질환(MRD) 검사 시장의 주요 기업 프로파일을 다음과 같은 매개 변수를 기반으로 프로파일링합니다 : 회사 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 성과 및 전략.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것으로 기대됩니다.
- 세계 미량 잔류 병변 검사 시장은 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 미량잔존병변검사 시장 분석에 사용되는 다양한 전략 매트릭스를 활용하여 의사결정을 원활하게 할 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 미세잔존질환 검사 시장 : 기술별, 2021-2033년
제5장 세계의 미세잔존질환 검사 시장 : 용도별, 2021-2033년
제6장 세계의 미세잔존질환 검사 시장 : 최종사용자별, 2021-2033년
제7장 세계의 미세잔존질환 검사 시장 : 지역별, 2021-2033년
제8장 경쟁 구도
제9장 애널리스트의 견해
제10장 참고문헌 및 조사 방법
KSMMinimal Residual Disease Testing Market is estimated to be valued at USD 2.89 Bn in 2026 and is expected to reach USD 6.39 Bn by 2033, growing at a compound annual growth rate (CAGR) of 12.0% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 2.89 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 12.00% | 2033 Value Projection: | USD 6.39 Bn |
Minimal Residual Disease (MRD) testing involves detecting tiny amounts of residual cancer cells that may remain in the body after initial treatment. It is an important tool for both hematologists and oncologists to monitor treatment response and predict outcomes for patients. MRD testing allows physicians to identify those who may be at higher risk of disease relapse earlier than other methods. This helps determine if additional therapies or closer monitoring is needed. Several technologies such as multiparameter flow cytometry, allele-specific oligonucleotide quantitative PCR, and next generation sequencing are used to detect MRD with high sensitivity. With growing applications of MRD testing across different types of blood cancers and improving technologies, the market is expected to witness significant growth in the coming years.
Market Dynamics
The global minimal residual disease testing market is driven by rising incidence of hematological cancers, increasing adoption of MRD testing in treatment monitoring, and growing awareness among physicians. However, lack of skilled professionals, high index of testing methods, and reimbursement issues in some regions are restraining the market growth. Various new product launches by players with improved sensitivity and automated platforms present key opportunities. For instance, personalized therapy and liquid biopsy techniques are emerging areas. Collaborations between companies and research institutes are also supporting market expansion into new geographies. The effects of the COVID-19 pandemic on healthcare resources is a challenge, though telemedicine and home-based sample collection aid continuity of MRD monitoring in current scenario.
Key Features of the Study
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global minimal residual disease testing market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study includes Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Guardant Health, Inc., Adaptive Biotechnologies, Invitae Corporation, ASURAGEN, INC., Invivoscribe, Inc., Laboratory Corporation of America Holdings, Natera, Inc., Sysmex Inostics, Inc., Amgen Inc., FOUNDATION MEDICINE, INC., Sebia, and Myriad Genetics, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global minimal residual disease testing market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global minimal residual disease testing market.
Market Segmentation
- Technology Insights (Revenue, USD Bn, 2021 - 2033)
- Flow Cytometry
- Polymerase chain reaction (PCR)
- Next generation sequencing
- Application Insights (Revenue, USD Bn, 2021 - 2033)
- Lymphoma
- Solid Tumors
- Others
- End User Insights (Revenue, USD Bn, 2021 - 2033)
- Hospitals
- Clinics
- Research Laboratories
- Others
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Bio-Rad Laboratories, Inc.
- F. Hoffmann-La Roche Ltd.
- Guardant Health, Inc.
- Adaptive Biotechnologies
- Invitae Corporation
- ASURAGEN, INC.
- Invivoscribe, Inc.
- Laboratory Corporation of America Holdings
- Natera, Inc.
- Sysmex Inostics, Inc.
- Amgen Inc.
- FOUNDATION MEDICINE, INC.
- Sebia
- Myriad Genetics, Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Technology
- Market Snapshot, By Application
- Market Snapshot, By End User
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Market Trends
- Epidemiology
- Recent Developments
- Acquisitions and Partnerships Scenario
- Funding and Investments
- PEST Analysis
- Porter's Analysis
4. Global Minimal Residual Disease Testing Market, By Technology, 2021 - 2033, (USD Bn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Flow Cytometry
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Polymerase chain reaction (PCR)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
5. Global Minimal Residual Disease Testing Market, By Application, 2021 - 2033, (USD Bn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Lymphoma
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Solid Tumors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Global Minimal Residual Disease Testing Market, By End User, 2021 - 2033, (USD Bn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospitals
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Clinics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Research Laboratories
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
7. Global Minimal Residual Disease Testing Market, By Region, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2021 - 2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Bn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Company Profiles
- Bio-Rad Laboratories, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- F. Hoffmann-La Roche Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Guardant Health, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Adaptive Biotechnologies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Invitae Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- ASURAGEN, INC.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Invivoscribe, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Laboratory Corporation of America Holdings
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Natera, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sysmex Inostics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- FOUNDATION MEDICINE, INC.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sebia
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Myriad Genetics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bio-Rad Laboratories, Inc.
9. Analyst View
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. References and Research Methodology
- References
- Research Methodology
- About us and Sales Contact
